Berenberg raises target for Qiagen stock to EUR 46.50
Published on 10/26/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBerenberg target raised
- Berenberg lifted its Qiagen target from EUR 40.00 to EUR 46.50 on October 22, 2026.
- QIAGEN reported USD 548 million in preliminary third-quarter 2026 sales and adjusted diluted earnings per share of USD 0.65.
- Qiagen stock costs EUR 45.14 at Lang & Schwarz on October 26, 2026 at 5:05 p.m. CEST, 0.20 percent above the Xetra close of October 23, 2026, and 5.17 percent below the 52-week high.
- QIAGEN plans to publish full third-quarter results on November 4, 2026.
Qiagen stock (ISIN NL0015002SN0) is trading at EUR 45.14 at Lang & Schwarz on October 26, 2026 at 5:05 p.m. CEST, plus 0.20 percent versus the Xetra close of October 23, 2026. Berenberg raised its price target from EUR 40.00 to EUR 46.50, according to MarketScreener on October 22, 2026, putting the target 3.01 percent above the Lang & Schwarz price.
Preliminary sales reached USD 548 million
QIAGEN reported preliminary third-quarter 2026 net sales of USD 548 million at both reported and constant exchange rates. Adjusted diluted earnings per share reached USD 0.65. The company also suspended its full-year 2026 outlook while its proposed transaction with EQT Private Equity remains pending, according to QIAGEN in a release dated October 21, 2026.
Price stays below EUR 47.60 high
The euro quotation stands inside its 52-week range of EUR 27.56 to EUR 47.60. At EUR 45.14, the stock is 5.17 percent below that high and 63.79 percent above the low. The QIA.DE quotation showed 386,458 shares traded on October 26, 2026, while the 52-week range and market figures were EUR 9.3 billion in market capitalization and a P/E ratio of 25.88.
Results date sets the next marker
QIAGEN plans to report full third-quarter 2026 results on November 4, 2026, at approximately 10:05 p.m. Frankfurt time, according to the October 21 release. That report will show whether the preliminary USD 548 million sales figure and USD 0.65 adjusted diluted earnings per share are confirmed.
Target and operating figures point higher
The analyst target and the preliminary results offer two different measures for investors. Berenberg's EUR 46.50 target is above the current euro quotation, while QIAGEN's USD 548 million sales figure and USD 0.65 adjusted diluted earnings per share describe the latest operating period. The company serves more than 500,000 customers and employed about 5,400 people as of September 30, 2026, according to QIAGEN.
Qiagen stock remains near its yearly high
The stock was trading at EUR 45.14 at Lang & Schwarz on October 26, 2026 at 5:05 p.m. CEST, plus 0.20 percent versus the Xetra close of EUR 45.05 on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.
Qiagen stock facts
- Company: Qiagen N.V.
- ISIN: NL0015002SN0
- Ticker: QGEN
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 26, 2026, 5:05 p.m. CEST): EUR 45.14
- Change versus Xetra close: plus 0.20 percent
- Xetra close (October 23, 2026): EUR 45.05
- Market capitalization: EUR 9.3 billion (as of October 26, 2026)
- 52-week range: EUR 27.56-EUR 47.60 (as of October 26, 2026)
- Sector / Industry: Biotechnology and Medical Research
Market context: Market report S&P 500.
